CA3053540A1 - Improved light therapy system and methods of use - Google Patents
Improved light therapy system and methods of use Download PDFInfo
- Publication number
- CA3053540A1 CA3053540A1 CA3053540A CA3053540A CA3053540A1 CA 3053540 A1 CA3053540 A1 CA 3053540A1 CA 3053540 A CA3053540 A CA 3053540A CA 3053540 A CA3053540 A CA 3053540A CA 3053540 A1 CA3053540 A1 CA 3053540A1
- Authority
- CA
- Canada
- Prior art keywords
- light source
- light
- spectral component
- blue
- lux
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001126 phototherapy Methods 0.000 title claims abstract description 156
- 238000000034 method Methods 0.000 title claims description 140
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 146
- 206010012289 Dementia Diseases 0.000 claims abstract description 73
- 210000004556 brain Anatomy 0.000 claims abstract description 65
- 238000011282 treatment Methods 0.000 claims abstract description 37
- 230000010355 oscillation Effects 0.000 claims abstract description 26
- 230000003931 cognitive performance Effects 0.000 claims abstract description 16
- 230000037147 athletic performance Effects 0.000 claims abstract description 15
- 230000006403 short-term memory Effects 0.000 claims abstract description 14
- 210000003994 retinal ganglion cell Anatomy 0.000 claims abstract description 9
- 230000003595 spectral effect Effects 0.000 claims description 250
- 208000010877 cognitive disease Diseases 0.000 claims description 117
- 230000004397 blinking Effects 0.000 claims description 86
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 79
- 238000005286 illumination Methods 0.000 claims description 60
- 230000000694 effects Effects 0.000 claims description 40
- 239000000090 biomarker Substances 0.000 claims description 37
- 208000024891 symptom Diseases 0.000 claims description 27
- 230000015654 memory Effects 0.000 claims description 26
- 230000001537 neural effect Effects 0.000 claims description 24
- 230000001149 cognitive effect Effects 0.000 claims description 23
- 230000006872 improvement Effects 0.000 claims description 22
- 230000036541 health Effects 0.000 claims description 20
- 230000006870 function Effects 0.000 claims description 18
- 230000007958 sleep Effects 0.000 claims description 18
- 230000009467 reduction Effects 0.000 claims description 17
- 230000004438 eyesight Effects 0.000 claims description 16
- 230000007423 decrease Effects 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 14
- 230000004770 neurodegeneration Effects 0.000 claims description 14
- 238000001228 spectrum Methods 0.000 claims description 14
- 208000027418 Wounds and injury Diseases 0.000 claims description 13
- 208000014674 injury Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 11
- 206010002022 amyloidosis Diseases 0.000 claims description 10
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 10
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 9
- 230000002490 cerebral effect Effects 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 230000000626 neurodegenerative effect Effects 0.000 claims description 9
- 230000019771 cognition Effects 0.000 claims description 8
- 238000011084 recovery Methods 0.000 claims description 8
- 238000012549 training Methods 0.000 claims description 8
- 230000001360 synchronised effect Effects 0.000 claims description 7
- 208000000044 Amnesia Diseases 0.000 claims description 6
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims description 6
- 210000000744 eyelid Anatomy 0.000 claims description 6
- 208000015756 familial Alzheimer disease Diseases 0.000 claims description 6
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 6
- 108700028369 Alleles Proteins 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 229960003530 donepezil Drugs 0.000 claims description 5
- 230000007505 plaque formation Effects 0.000 claims description 5
- 239000013589 supplement Substances 0.000 claims description 5
- 230000003542 behavioural effect Effects 0.000 claims description 4
- 230000003930 cognitive ability Effects 0.000 claims description 4
- 230000033001 locomotion Effects 0.000 claims description 4
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 4
- 229960004640 memantine Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 3
- 229960003980 galantamine Drugs 0.000 claims description 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 3
- 238000000554 physical therapy Methods 0.000 claims description 3
- 229960004136 rivastigmine Drugs 0.000 claims description 3
- 230000006641 stabilisation Effects 0.000 claims description 3
- 238000011105 stabilization Methods 0.000 claims description 3
- 230000007704 transition Effects 0.000 claims description 3
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 2
- 208000031124 Dementia Alzheimer type Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000001934 delay Effects 0.000 claims description 2
- 101150037123 APOE gene Proteins 0.000 claims 1
- 230000000670 limiting effect Effects 0.000 description 20
- 241000282412 Homo Species 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 230000006999 cognitive decline Effects 0.000 description 15
- 238000003745 diagnosis Methods 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 13
- 239000003086 colorant Substances 0.000 description 12
- 230000006735 deficit Effects 0.000 description 12
- 230000007177 brain activity Effects 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 230000004927 fusion Effects 0.000 description 11
- 230000000069 prophylactic effect Effects 0.000 description 11
- 230000000007 visual effect Effects 0.000 description 11
- 230000001771 impaired effect Effects 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 101710095339 Apolipoprotein E Proteins 0.000 description 8
- 206010027175 memory impairment Diseases 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 208000026139 Memory disease Diseases 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 7
- 230000027288 circadian rhythm Effects 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 230000001073 episodic memory Effects 0.000 description 6
- 238000002600 positron emission tomography Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 5
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 208000028698 Cognitive impairment Diseases 0.000 description 4
- 208000003098 Ganglion Cysts Diseases 0.000 description 4
- 208000005400 Synovial Cyst Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000008449 language Effects 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000006984 memory degeneration Effects 0.000 description 4
- 208000023060 memory loss Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000009226 pathological process of alzheimers disease Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000035778 pathophysiological process Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 3
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 230000007082 Aβ accumulation Effects 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 206010021034 Hypometabolism Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010052143 Ocular discomfort Diseases 0.000 description 3
- 206010035148 Plague Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000002060 circadian Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 108091008695 photoreceptors Proteins 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 230000003976 synaptic dysfunction Effects 0.000 description 3
- 210000003478 temporal lobe Anatomy 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000007333 Brain Concussion Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 2
- 102000016550 Complement Factor H Human genes 0.000 description 2
- 108010053085 Complement Factor H Proteins 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- 206010034719 Personality change Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003942 amyloidogenic effect Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 208000003464 asthenopia Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008632 circadian clock Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 208000017004 dementia pugilistica Diseases 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
- 230000004313 glare Effects 0.000 description 2
- 210000004884 grey matter Anatomy 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000010855 neuropsychological testing Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000001020 rhythmical effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000000857 visual cortex Anatomy 0.000 description 2
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000027647 Cerebral Cortical Thinning Diseases 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 206010052128 Glare Diseases 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 101150042248 Mgmt gene Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010065604 Suicidal behaviour Diseases 0.000 description 1
- 206010042635 Suspiciousness Diseases 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 238000011952 auditory verbal learning test Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000007166 healthy aging Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000008906 neuronal response Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 230000032554 response to blue light Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000012034 trail making test Methods 0.000 description 1
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0618—Psychological treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B45/00—Circuit arrangements for operating light-emitting diodes [LED]
- H05B45/20—Controlling the colour of the light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B2018/1807—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using light other than laser radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0022—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the tactile sense, e.g. vibrations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0027—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the hearing sense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0044—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the sight sense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0055—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with electric or electro-magnetic fields
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0072—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with application of electrical currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0077—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with application of chemical or pharmacological stimulus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/332—Force measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3358—Measuring barometric pressure, e.g. for compensation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3553—Range remote, e.g. between patient's home and doctor's office
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3561—Range local, e.g. within room or hospital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3569—Range sublocal, e.g. between console and disposable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3584—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or bluetooth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3592—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
- A61M2205/505—Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
- A61M2230/06—Heartbeat rate only
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/30—Blood pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/50—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/63—Motion, e.g. physical activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
- A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
- A61N2005/0648—Applicators worn by the patient the applicator adapted to be worn on the head the light being directed to the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Developmental Disabilities (AREA)
- Hospice & Palliative Care (AREA)
- Social Psychology (AREA)
- Psychiatry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Acoustics & Sound (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Radiation-Therapy Devices (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459138P | 2017-02-15 | 2017-02-15 | |
| US62/459,138 | 2017-02-15 | ||
| US201762595065P | 2017-12-05 | 2017-12-05 | |
| US62/595,065 | 2017-12-05 | ||
| PCT/US2018/018250 WO2018152255A1 (en) | 2017-02-15 | 2018-02-14 | Improved light therapy system and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3053540A1 true CA3053540A1 (en) | 2018-08-23 |
Family
ID=63169597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3053540A Pending CA3053540A1 (en) | 2017-02-15 | 2018-02-14 | Improved light therapy system and methods of use |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11813475B2 (enExample) |
| EP (1) | EP3582852A4 (enExample) |
| JP (2) | JP7458786B2 (enExample) |
| CA (1) | CA3053540A1 (enExample) |
| WO (1) | WO2018152255A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109549643A (zh) * | 2018-11-19 | 2019-04-02 | 浙江升腾生物科技有限公司 | 智力训练方法和智力训练仪 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11465013B2 (en) | 2012-08-31 | 2022-10-11 | Blue Goji Llc | System and method for targeted neurological therapy using brainwave entrainment |
| US11388799B2 (en) * | 2012-11-08 | 2022-07-12 | Applied Biophotonics Ltd. | Distributed photobiomodulation therapy system and method |
| KR20230161532A (ko) | 2015-11-24 | 2023-11-27 | 메사추세츠 인스티튜트 오브 테크놀로지 | 치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법 |
| WO2018094230A2 (en) | 2016-11-17 | 2018-05-24 | Cognito Therapeutics, Inc. | Methods and systems for neural stimulation via auditory stimulation |
| US11433253B2 (en) | 2017-02-15 | 2022-09-06 | The Regents Of The University Of California | Light therapy system and methods of use |
| EP3694464B1 (en) | 2017-10-10 | 2025-12-10 | Massachusetts Institute of Technology | Systems for preventing, mitigating, and/or treating dementia |
| US11964109B2 (en) * | 2018-03-09 | 2024-04-23 | Georgia Tech Research Corporation | Systems and methods for driving neural activity to control brain signaling and gene expression |
| US10478635B1 (en) | 2018-10-22 | 2019-11-19 | Joovv, Inc. | Photobiomodulation therapy systems and methods |
| US11458328B2 (en) | 2018-10-22 | 2022-10-04 | Joovv, Inc. | Photobiomodulation therapy device accessories |
| EP3886682A1 (en) * | 2018-11-30 | 2021-10-06 | Spectrawave, Inc. | Interleaved light sources and methods of their use |
| WO2020203053A1 (ja) * | 2019-03-29 | 2020-10-08 | ソニー株式会社 | 発光装置、表示装置および電子機器 |
| CN110237434A (zh) * | 2019-06-18 | 2019-09-17 | 深圳晶多宝科技有限公司 | 一种理疗仪及其在调节人体三高中的应用 |
| WO2021076756A1 (en) | 2019-10-15 | 2021-04-22 | Jelikalite Llc | Head wearable light therapy device |
| US20230092770A1 (en) * | 2019-10-15 | 2023-03-23 | Jelikalite Llc | Methods and devices for photobiomodulation |
| EP3824952A1 (en) * | 2019-11-22 | 2021-05-26 | Seaborough Life Science B.V. | General lighting with photobiomodulation |
| US12083286B2 (en) * | 2020-03-26 | 2024-09-10 | Brian Neltner | System and method for generating Ganzfeld effect |
| US20220184413A1 (en) * | 2020-05-27 | 2022-06-16 | Norb Lighting, LLC. | Grow light and ocular light therapy arrangements and methods for growing plants and for treating neurological disorders |
| US12005268B2 (en) * | 2020-05-27 | 2024-06-11 | Norb Lighting, LLC | Ocular light therapy arrangement and method for treating neurological disorders |
| AU2021316037A1 (en) * | 2020-07-27 | 2023-03-02 | Cognito Therapeutics, Inc. | Sensory gamma stimulation therapy improves sleep quality and maintains functional ability in alzheimers disease patients |
| KR102563132B1 (ko) * | 2020-10-28 | 2023-08-03 | 주식회사 지엘 | 인지기능 재활훈련 시스템 |
| US11730917B2 (en) | 2020-10-29 | 2023-08-22 | Optoceutics ApS | Gamma stimulation pulsing light source system with dosage adjustment for gaze angle |
| US20240032167A1 (en) * | 2020-11-09 | 2024-01-25 | Queensland University Of Technology | Device, method and system for biologically balanced lighting |
| CA3211383A1 (en) * | 2021-03-09 | 2022-09-15 | Zachary MALCHANO | Methods and systems for slowing brain atrophy |
| TWI851983B (zh) * | 2021-03-25 | 2024-08-11 | 國立陽明交通大學 | 周圍環境中之光系統 |
| JP2022173837A (ja) * | 2021-05-10 | 2022-11-22 | シャント テクノロジーズ， インコーポレイテッド | 光子変調を用いて哺乳動物のホルモンを調節する方法 |
| EP4178669A1 (en) | 2021-07-05 | 2023-05-17 | Danmarks Tekniske Universitet | Phototherapeutic apparatus |
| US20230256262A1 (en) * | 2021-10-21 | 2023-08-17 | Optoceutics ApS | Phototherapeutic apparatus |
| CN118475385A (zh) * | 2021-10-27 | 2024-08-09 | 坪田实验室股份有限公司 | 通过光刺激治疗疾病的方法和用于其的装置 |
| WO2023122281A1 (en) * | 2021-12-23 | 2023-06-29 | Georgia Tech Research Corporation | Brain stimulation systems and methods |
| DE112023000628T5 (de) * | 2022-01-20 | 2024-11-21 | Korrus, Inc. | Lichttherapie-System und Verfahren |
| NZ809676A (en) * | 2022-04-11 | 2024-11-29 | Suntracker Tech Ltd | Visible light chromophore excitation for microorganism control |
| CN115006681B (zh) * | 2022-06-05 | 2025-01-28 | 上海中医药大学 | 一种可灵活调参的闪烁光刺激神经调控装置 |
| WO2024218088A1 (en) | 2023-04-20 | 2024-10-24 | Optoceutics ApS | Phototherapeutic apparatus |
| CN116807475A (zh) * | 2023-08-11 | 2023-09-29 | 北京理工大学 | 一种精神状态评估方法及系统 |
| KR20250036492A (ko) * | 2023-09-07 | 2025-03-14 | 서울대학교병원 | 노인의 인지능력을 개선하는 뇌파 활성화 장치 |
| US20250191483A1 (en) * | 2023-12-07 | 2025-06-12 | BlueForge Alliance | Systems and methods for using a vocational mask with a hyper-enabled worker |
| US20250288772A1 (en) * | 2024-03-12 | 2025-09-18 | Recharge Pod Limited | Pod Chamber For Immersing A User In A Multisensory Experience Delivered In Concert With An Audio Beat Frequency |
| WO2025192632A1 (ja) * | 2024-03-15 | 2025-09-18 | 京セラ株式会社 | 制御装置、制御方法、および制御システム |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8308784B2 (en) * | 2006-08-24 | 2012-11-13 | Jackson Streeter | Low level light therapy for enhancement of neurologic function of a patient affected by Parkinson's disease |
| WO2006079199A1 (en) | 2005-01-25 | 2006-08-03 | Tir Systems Ltd. | Method and apparatus for illumination and communication |
| US7575589B2 (en) * | 2006-01-30 | 2009-08-18 | Photothera, Inc. | Light-emitting device and method for providing phototherapy to the brain |
| ES2583487T3 (es) * | 2007-05-25 | 2016-09-21 | Thomas Jefferson University | Método para mejorar la concentración y/o la memoria en un sujeto que lo necesita |
| KR20100027186A (ko) | 2007-05-31 | 2010-03-10 | 코닌클리즈케 필립스 일렉트로닉스 엔.브이. | 조명 및 생리적 자극 제공 방법 및 시스템 |
| US20090005837A1 (en) | 2007-06-29 | 2009-01-01 | Ruth Olmstead | Method and apparatus for stimulating the neurochemistry of the brain resulting in increased overall brain function, cognitive performance, and intelligence quota |
| WO2010122446A1 (en) | 2009-04-16 | 2010-10-28 | Koninklijke Philips Electronics N.V. | Illumination device and method for reducing sleep inertia or controlling alertness |
| EP2520134B1 (en) * | 2009-10-08 | 2015-03-25 | Delos Living, LLC | Led lighting system |
| EP2772278B1 (en) | 2011-10-25 | 2017-08-02 | Kanazawa Medical University | Light exposure device for improving cognitive symptoms and depression symptoms |
| US9352170B1 (en) | 2012-01-31 | 2016-05-31 | Christina Davis | Spectral light therapy for autism spectral disorders |
| MX2014012374A (es) | 2012-04-14 | 2015-04-17 | Intra Cellular Therapies Inc | Compuestos organicos. |
| US10155121B2 (en) * | 2012-08-25 | 2018-12-18 | National Chiao Tung University | Stimuli generating methods, devices and control systems to induce visual evoked potentials using imperceptible flickering multi-color lights |
| US9877361B2 (en) * | 2012-11-08 | 2018-01-23 | Applied Biophotonics Ltd | Phototherapy system and process including dynamic LED driver with programmable waveform |
| US20160008568A1 (en) * | 2013-02-20 | 2016-01-14 | Sarah Beth Attia | Relaxation apparatus and method |
| KR20160055103A (ko) * | 2013-03-15 | 2016-05-17 | 아담 제이 사이먼 | 뇌 건강의 다중-모드 생리적 자극 및 평가를 위한 시스템 및 시그너처 |
| RU2707365C2 (ru) | 2013-07-25 | 2019-11-26 | Конинклейке Филипс Н.В. | Система и способ проведения светотерапии и изменения циркадного ритма |
| WO2015184019A1 (en) | 2014-05-27 | 2015-12-03 | Innosys, Inc. | Lighting systems |
| CA3017104A1 (en) | 2015-03-09 | 2016-09-15 | Circadian Zirclight Inc. | Systems and methods for controlling environmental illumination |
| KR20230161532A (ko) | 2015-11-24 | 2023-11-27 | 메사추세츠 인스티튜트 오브 테크놀로지 | 치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법 |
| US11338107B2 (en) | 2016-08-24 | 2022-05-24 | Delos Living Llc | Systems, methods and articles for enhancing wellness associated with habitable environments |
| WO2018094230A2 (en) | 2016-11-17 | 2018-05-24 | Cognito Therapeutics, Inc. | Methods and systems for neural stimulation via auditory stimulation |
| US11433253B2 (en) | 2017-02-15 | 2022-09-06 | The Regents Of The University Of California | Light therapy system and methods of use |
| US10960225B2 (en) | 2017-10-10 | 2021-03-30 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function |
| EP3694464B1 (en) | 2017-10-10 | 2025-12-10 | Massachusetts Institute of Technology | Systems for preventing, mitigating, and/or treating dementia |
| US10129937B1 (en) | 2018-01-10 | 2018-11-13 | Abl Ip Holding Llc | Controlling flicker caused by multiple light sources |
-
2018
- 2018-02-14 EP EP18754662.7A patent/EP3582852A4/en active Pending
- 2018-02-14 US US16/486,136 patent/US11813475B2/en active Active
- 2018-02-14 WO PCT/US2018/018250 patent/WO2018152255A1/en not_active Ceased
- 2018-02-14 CA CA3053540A patent/CA3053540A1/en active Pending
- 2018-02-14 JP JP2019543972A patent/JP7458786B2/ja active Active
-
2022
- 2022-12-23 JP JP2022207181A patent/JP2023040080A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109549643A (zh) * | 2018-11-19 | 2019-04-02 | 浙江升腾生物科技有限公司 | 智力训练方法和智力训练仪 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7458786B2 (ja) | 2024-04-01 |
| JP2020507414A (ja) | 2020-03-12 |
| WO2018152255A1 (en) | 2018-08-23 |
| EP3582852A1 (en) | 2019-12-25 |
| US11813475B2 (en) | 2023-11-14 |
| EP3582852A4 (en) | 2020-11-25 |
| JP2023040080A (ja) | 2023-03-22 |
| US20200269065A1 (en) | 2020-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11813475B2 (en) | Light therapy system and methods of use | |
| US12168144B2 (en) | Light therapy system and methods of use | |
| Muralidharan et al. | Light and myopia: from epidemiological studies to neurobiological mechanisms | |
| Figueiro et al. | Non-visual effects of light: How to use light to promote circadian entrainment and elicit alertness | |
| West et al. | Blue light from light-emitting diodes elicits a dose-dependent suppression of melatonin in humans | |
| LeGates et al. | Light as a central modulator of circadian rhythms, sleep and affect | |
| Royer et al. | Light therapy for seniors in long term care | |
| Park et al. | Effects of color temperature and brightness on electroencephalogram alpha activity in a polychromatic light-emitting diode | |
| Figueiro et al. | Implications of controlled short-wavelength light exposure for sleep in older adults | |
| Grant et al. | Daytime exposure to short wavelength-enriched light improves cognitive performance in sleep-restricted college-aged adults | |
| Münch et al. | The effect of light on humans | |
| Lok et al. | Impact of daytime spectral tuning on cognitive function | |
| Blume et al. | Effects of calibrated blue–yellow changes in light on the human circadian clock | |
| Schöllhorn et al. | Effects of nature-adapted lighting solutions (“Virtual Sky”) on subjective and objective correlates of sleepiness, well-being, visual and cognitive performance at the workplace | |
| Figueiro et al. | A personal light-treatment device for improving sleep quality in the elderly: dynamics of nocturnal melatonin suppression at two exposure levels | |
| Mazurek et al. | Investigating the effects of indoor lighting on measures of brain health in older adults: protocol for a cross-over randomized controlled trial | |
| Gómez-Vela et al. | Acute effect of orange chromatic environment on perceived health status, pain, and vital signs during chemotherapy treatment | |
| Sinoo | Light conditions in nursing homes: visual comfort and visual functioning of residents | |
| Geoffroy et al. | Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force | |
| Gerhardsson et al. | Light, activity and sleep in my daily life:: Design of an online intervention targeting changes to routines and the home | |
| Fernandez et al. | Translation and Processing of Light by the Non-Image Forming Visual System–Context, Mechanisms and Applications | |
| Leggett | Integrating Light-Based Therapies and Diagnostic Tools for Mild Cognitive Impairment: Effects on Neuroinflammation, Amyloid Beta, and Alertness | |
| Hanifin | Circadian, neuroendocrine and neurobehavioral effects of polychromatic light in humans | |
| Bhardwaj | Light, Molecular Mechanism & Sleep (Basics): Light Is the Governor of the Universe | |
| Inoue et al. | Cognitive task performance in simulated night shifts: impact of optical filtering on 450–500-nm wavelength light under bright lighting conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230213 |
|
| EEER | Examination request |
Effective date: 20230213 |
|
| EEER | Examination request |
Effective date: 20230213 |
|
| EEER | Examination request |
Effective date: 20230213 |